Technology ID
TAB-892
Method for the Treatment of Multiple Sclerosis
E-Numbers
E-143-2002-0
E-143-2002-1
Co-Inventors
Martin, Roland
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Immunology
Lead IC
NINDS
The invention relates to the discovery that humanized antibodies to the interleukin-2 receptor (IL-2R) such as (daclizumab) are effective in treating multiple sclerosis (MS). In particular, it has been discovered that patients who have failed to respond to therapy with interferon-beta show dramatic improvement when treated with daclizumab, with patients showing both a reduction in the total number of lesions and cessation of appearance of new lesions during the treatment period. Daclizumab is effective both in combination with interferon-beta and alone.
Licensing Contact: